News and Articles

A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

Newly added funding closes critical gap and enables planned trial initiation in early 2026

Redefining Vision: Tucson’s Taylor Talbot and the Power of Possibility

New Hope for Retinitis Pigmentosa: FDA Grants Fast Track Designation for ADX-2191

FDA Fast Tracks Potential RP Treatment Aldeyra’s ADX-2191 has received Fast Track Designation from the FDA for retinitis pigmentosa. With no approved treatments currently available for most RP patients, this milestone could help speed the development of a promising new therapy.

Long-Term Results Show Promise for MCO-010 in Retinitis Pigmentosa

🌟 Long-Term Results Show Promise for RP Therapy At the 2025 ASRS meeting, researchers shared 2-year results showing that MCO-010, an optogenetic therapy, provided lasting vision improvements for patients with advanced retinitis pigmentosa. Unlike traditional gene therapies, MCO-010 is gene-agnostic, meaning it could help a broad range of patients regardless of mutation.

Hope in Focus: 24-Month Results from the SKYLINE Gene Therapy Trial for X-Linked Retinitis Pigmentosa

✨ New Hope for XLRP Patients The SKYLINE Phase 2 trial of laruzova, a gene therapy for X-linked retinitis pigmentosa, has shown promising vision improvements at 24 months. With the pivotal VISTA Phase 3 trial now fully enrolled, this breakthrough research moves us one step closer to potential treatment for this rare inherited blindness.

First Patients Treated in New jCell Clinical Trial for Retinitis Pigmentosa

First Patients Treated in jCell RP Trial jCyte has launched its Phase 2 JC02-88 trial testing jCell, a potential regenerative therapy for retinitis pigmentosa. This study could bring the first treatment option to the majority of RP patients, offering hope across all genetic subtypes.